BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
After guiding BlueRock Therapeutics and its potential Parkinson’s disease stem cell therapy into the clinic and to a $1 billion acquisition by Bayer, Emile Nuwaysir is taking on gene therapy startup Ensoma as CEO.
As part of the Takeda deal, Ensoma will do preclinical research for therapies in up to five rare disease indications, and both companies will work on Investigational New Drug-enabling studies.
Ensoma announced the appointment of Jim Burns, Ph.D., as chief executive officer and a member of the company’s board of directors.
Ensoma announced the closing of an extension of its Series B financing by $50 million, bringing the total size of the funding round to $135 million.
Ensoma today announced the closing of its previously announced acquisition of Twelve Bio ApS.
Ensoma, a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system, announced the completion of an $85 million financing.
Ensoma today announced additions to the Company’s scientific advisory board (SAB)
  • NextGen Class of 2022
  • 2024 Best Places to Work